UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000025037
Receipt No. R000028807
Scientific Title A pharmacokinetic study of sodium phenylbutyrate in refractory pediatric cholestasis disease
Date of disclosure of the study information 2016/11/29
Last modified on 2018/07/18

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A pharmacokinetic study of sodium phenylbutyrate in refractory pediatric cholestasis disease
Acronym A pharmacokinetic study of sodium phenylbutyrate in refractory pediatric cholestasis disease
Scientific Title A pharmacokinetic study of sodium phenylbutyrate in refractory pediatric cholestasis disease
Scientific Title:Acronym A pharmacokinetic study of sodium phenylbutyrate in refractory pediatric cholestasis disease
Region
Japan

Condition
Condition Refractory pediatric cholestasis disease (progressive familial intrahepatic cholestasis, primary biliary cirrhosis, primary sclerosing cholangitis, Alagille syndrome, drug-induced cholestatic liver injury, biliary atresia, etc)
Classification by specialty
Pediatrics
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To clarify pharmacokinetic properties of sodium phenylbutyrate and its metabolites in refractory pediatric cholestasis disease
Basic objectives2 PK,PD
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2 Explanatory
Developmental phase Phase I

Assessment
Primary outcomes To determine concentration of phenylbutylate and its metabolites in blood and urine after oral administration of sodium phenylbutyrate
Key secondary outcomes 1) Plasma amino acid fraction (isoleucine, glutamine, glutamic acid, argineine), and anmonia
2) Adverse events

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 To administer sodium phenylbutylate orally at less than 200mg/kg.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
6 months-old <=
Age-upper limit
216 months-old >
Gender Male and Female
Key inclusion criteria 1) Subjects with diagnosis of refractory pediatric cholestasis disease.
2) Hospitalised patients.
3) Those who can intake medicine orally.
4) Those who can receive the observation essential for this study.
5) Subjects who have been determined eligible by principal investigator or sub-investigator from physical and clinical examinations.
6) Those who have agreed with participating in this study by written informed consent prior to the study (patients or legally acceptable representative).
Key exclusion criteria 1) Those who have hypersensitivity with phenylbutylate, its metabolites, drug additives and/or benzoate, etc
2) Subjects with congestive heart failure, kidney failure, and/or hypernatremia with edema
3) Subjects with renal dysfunction
4) Subjects with liver cirrhosis
5) Subjects who have been determined ineligible by principal investigator or sub-investigator
Target sample size 10

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Kei Minowa
Organization Juntendo University, Faculty of Medicine
Division name Department of Pediatrics
Zip code
Address 2-1-1, Hongo, Bunkyo-ward, Tokyo
TEL 03-3813-3111
Email kminowa@juntendo.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Kei Minowa
Organization Juntendo University, Faculty of Medicine
Division name Department of Pediatrics
Zip code
Address 2-1-1, Hongo, Bunkyo-ward, Tokyo
TEL 03-3813-3111
Homepage URL
Email kminowa@juntendo.ac.jp

Sponsor
Institute Juntendo University
Institute
Department

Funding Source
Organization Japan Agency for Medical Research and Development
Organization
Division
Category of Funding Organization Government offices of other countries
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 順天堂大学医学部附属順天堂医院(東京都)、神栖済生会病院(茨城県)、東京大学 大学院薬学系研究科 分子薬物動態学教室(東京都)、千葉こども病院(千葉県)、藤田保健衛生大学病院(愛知県)、大阪大学医学部附属病院(大阪府)、済生会横浜市東部病院(神奈川県)

Other administrative information
Date of disclosure of the study information
2016 Year 11 Month 29 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2016 Year 11 Month 14 Day
Date of IRB
Anticipated trial start date
2016 Year 11 Month 14 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2016 Year 11 Month 29 Day
Last modified on
2018 Year 07 Month 18 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028807

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.